My watch list  

5 Current news from israel

matching the following criteria

BGU and University of Colorado Researchers Develop Novel “Smart” Drug that Targets and Reduces Site-Specific Inflammation


Ben-Gurion University of the Negev and University of Colorado researchers have used a highly novel approach to create a dynamic ‘smart’ drug that is attentive to the degree of the inflammation. The three describe a novel creative development of an anti-inflammatory engineered protein in the ...


image description
New hope for Gaucher patients


What causes brain damage and inflammation in severe cases of Gaucher disease? Little is known about the events that lead to brain pathology in some forms of the disease, and there is currently no treatment available – a bleak outlook for sufferers and their families. Now, scientists at the ...


Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research


Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine. Professor Apte is chairman of the Shraga Segal Department of Microbiology and Immunology and vice dean of the Basic Sciences ...


Ben-Gurion University of the Negev Alzheimer's Researcher demostrates specific immune response to vaccine


A researcher who is working on a vaccine for Alzheimer’s disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer’s patients. This continuing research at Ben-Gurion University of ...


Kamada Reports Positive Phase II Data with Inhaled AAT in Cystic Fibrosis

The Results Demonstrate the Product Has an Excellent Safety Profile and Shows Promising Signs of Efficacy, as Indicated by a Reduction in Lung Inflammation


Kamada announced positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow® Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE